Vanguard Personalized Indexing Management LLC Boosts Stock Position in Koninklijke Philips N.V. $PHG

Vanguard Personalized Indexing Management LLC boosted its holdings in Koninklijke Philips N.V. (NYSE:PHG) by 15.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,610 shares of the technology company’s stock after buying an additional 6,978 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Koninklijke Philips were worth $1,264,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of PHG. GAMMA Investing LLC boosted its stake in Koninklijke Philips by 25.8% in the first quarter. GAMMA Investing LLC now owns 13,789 shares of the technology company’s stock valued at $350,000 after acquiring an additional 2,826 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in Koninklijke Philips by 1.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 100,140 shares of the technology company’s stock valued at $2,544,000 after acquiring an additional 1,137 shares in the last quarter. Oppenheimer Asset Management Inc. boosted its stake in Koninklijke Philips by 1.5% in the first quarter. Oppenheimer Asset Management Inc. now owns 164,789 shares of the technology company’s stock valued at $4,186,000 after acquiring an additional 2,464 shares in the last quarter. Global Assets Advisory LLC acquired a new position in Koninklijke Philips in the first quarter valued at $445,000. Finally, Wealthquest Corp acquired a new position in Koninklijke Philips in the first quarter valued at $116,000. Institutional investors and hedge funds own 13.67% of the company’s stock.

Koninklijke Philips Stock Performance

NYSE PHG opened at $28.54 on Friday. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.69. Koninklijke Philips N.V. has a 52-week low of $21.48 and a 52-week high of $32.25. The business’s 50-day moving average price is $27.69 and its 200 day moving average price is $25.35. The firm has a market cap of $27.48 billion, a P/E ratio of 150.18, a P/E/G ratio of 0.77 and a beta of 0.82.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings results on Tuesday, July 29th. The technology company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.12. Koninklijke Philips had a return on equity of 11.95% and a net margin of 1.00%.The firm had revenue of $5.05 billion for the quarter, compared to analyst estimates of $4.35 billion. On average, equities research analysts expect that Koninklijke Philips N.V. will post 1.63 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on PHG shares. Weiss Ratings restated a “sell (d+)” rating on shares of Koninklijke Philips in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Koninklijke Philips from a “buy” rating to a “hold” rating in a research note on Saturday, August 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.